239 related articles for article (PubMed ID: 26876199)
1. Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells.
Chan JY; LaPara K; Yee D
Oncogene; 2016 Aug; 35(32):4235-43. PubMed ID: 26876199
[TBL] [Abstract][Full Text] [Related]
2. Targeting Insulin Receptor in Breast Cancer Using Small Engineered Protein Scaffolds.
Chan JY; Hackel BJ; Yee D
Mol Cancer Ther; 2017 Jul; 16(7):1324-1334. PubMed ID: 28468775
[TBL] [Abstract][Full Text] [Related]
3. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
[TBL] [Abstract][Full Text] [Related]
4. Controlled dimerization of insulin-like growth factor-1 and insulin receptors reveals shared and distinct activities of holo and hybrid receptors.
Chen J; Nagle AM; Wang YF; Boone DN; Lee AV
J Biol Chem; 2018 Mar; 293(10):3700-3709. PubMed ID: 29330302
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to tamoxifen is associated with loss of the type I insulin-like growth factor receptor: implications for breast cancer treatment.
Fagan DH; Uselman RR; Sachdev D; Yee D
Cancer Res; 2012 Jul; 72(13):3372-80. PubMed ID: 22573715
[TBL] [Abstract][Full Text] [Related]
6. Loss of E-cadherin Enhances IGF1-IGF1R Pathway Activation and Sensitizes Breast Cancers to Anti-IGF1R/InsR Inhibitors.
Nagle AM; Levine KM; Tasdemir N; Scott JA; Burlbaugh K; Kehm J; Katz TA; Boone DN; Jacobsen BM; Atkinson JM; Oesterreich S; Lee AV
Clin Cancer Res; 2018 Oct; 24(20):5165-5177. PubMed ID: 29941485
[No Abstract] [Full Text] [Related]
7. IGF-1R pathway activation as putative biomarker for linsitinib therapy to revert tamoxifen resistance in ER-positive breast cancer.
Kruger DT; Alexi X; Opdam M; Schuurman K; Voorwerk L; Sanders J; van der Noort V; Boven E; Zwart W; Linn SC
Int J Cancer; 2020 Apr; 146(8):2348-2359. PubMed ID: 31490549
[TBL] [Abstract][Full Text] [Related]
8. IGF-1 Receptor Modulates FoxO1-Mediated Tamoxifen Response in Breast Cancer Cells.
Vaziri-Gohar A; Zheng Y; Houston KD
Mol Cancer Res; 2017 Apr; 15(4):489-497. PubMed ID: 28096479
[TBL] [Abstract][Full Text] [Related]
9. Compensatory role of insulin-like growth factor 1 receptor in estrogen receptor signaling pathway and possible therapeutic target for hormone therapy-resistant breast cancer.
Iida M; Tsuboi K; Niwa T; Ishida T; Hayashi SI
Breast Cancer; 2019 May; 26(3):272-281. PubMed ID: 30328006
[TBL] [Abstract][Full Text] [Related]
10. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
Sachdev D; Li SL; Hartell JS; Fujita-Yamaguchi Y; Miller JS; Yee D
Cancer Res; 2003 Feb; 63(3):627-35. PubMed ID: 12566306
[TBL] [Abstract][Full Text] [Related]
11. A kinome-wide screen identifies the insulin/IGF-I receptor pathway as a mechanism of escape from hormone dependence in breast cancer.
Fox EM; Miller TW; Balko JM; Kuba MG; Sánchez V; Smith RA; Liu S; González-Angulo AM; Mills GB; Ye F; Shyr Y; Manning HC; Buck E; Arteaga CL
Cancer Res; 2011 Nov; 71(21):6773-84. PubMed ID: 21908557
[TBL] [Abstract][Full Text] [Related]
12. Classifying the adverse mitogenic mode of action of insulin analogues using a novel mechanism-based genetically engineered human breast cancer cell panel.
ter Braak B; Siezen CL; Kannegieter N; Koedoot E; van de Water B; van der Laan JW
Arch Toxicol; 2014 Apr; 88(4):953-66. PubMed ID: 24464500
[TBL] [Abstract][Full Text] [Related]
13. Combined and individual tumor-specific expression of insulin-like growth factor-I receptor, insulin receptor and phospho-insulin-like growth factor-I receptor/insulin receptor in primary breast cancer: Implications for prognosis in different treatment groups.
Björner S; Rosendahl AH; Simonsson M; Markkula A; Jirström K; Borgquist S; Rose C; Ingvar C; Jernström H
Oncotarget; 2017 Feb; 8(6):9093-9107. PubMed ID: 28030849
[TBL] [Abstract][Full Text] [Related]
14. Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.
Ofer P; Heidegger I; Eder IE; Schöpf B; Neuwirt H; Geley S; Klocker H; Massoner P
Mol Endocrinol; 2015 Dec; 29(12):1694-707. PubMed ID: 26452103
[TBL] [Abstract][Full Text] [Related]
15. Global characterization of signalling networks associated with tamoxifen resistance in breast cancer.
Browne BC; Hochgräfe F; Wu J; Millar EK; Barraclough J; Stone A; McCloy RA; Lee CS; Roberts C; Ali NA; Boulghourjian A; Schmich F; Linding R; Farrow L; Gee JM; Nicholson RI; O'Toole SA; Sutherland RL; Musgrove EA; Butt AJ; Daly RJ
FEBS J; 2013 Nov; 280(21):5237-57. PubMed ID: 23876235
[TBL] [Abstract][Full Text] [Related]
16. Novel nuclear localization and potential function of insulin-like growth factor-1 receptor/insulin receptor hybrid in corneal epithelial cells.
Wu YC; Zhu M; Robertson DM
PLoS One; 2012; 7(8):e42483. PubMed ID: 22879999
[TBL] [Abstract][Full Text] [Related]
17. Insulin-mediated signaling promotes proliferation and survival of glioblastoma through Akt activation.
Gong Y; Ma Y; Sinyuk M; Loganathan S; Thompson RC; Sarkaria JN; Chen W; Lathia JD; Mobley BC; Clark SW; Wang J
Neuro Oncol; 2016 Jan; 18(1):48-57. PubMed ID: 26136493
[TBL] [Abstract][Full Text] [Related]
18. Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease.
Chakraborty A; Hatzis C; DiGiovanna MP
Breast Cancer Res Treat; 2017 May; 163(1):37-50. PubMed ID: 28236033
[TBL] [Abstract][Full Text] [Related]
19. Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor.
Zeng X; Zhang H; Oh A; Zhang Y; Yee D
Breast Cancer Res Treat; 2012 May; 133(1):117-26. PubMed ID: 21850397
[TBL] [Abstract][Full Text] [Related]
20. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]